A new two-strip TLC method for the quality control of technetium-99m mercaptoacetyl-triglycine (99mTc-MAG3)
Published on: 14 March 2018
Skip to main content
Published on: 14 March 2018
Published on: 27 February 2018
Published on: 20 February 2018
Published on: 22 January 2018
Published on: 17 June 2016
Published on: 2 June 2016
Published on: 29 June 2017
Published on: 10 October 2016
Published on: 21 March 2016
More than 500 institutions have partnered with SpringerOpen through the membership program. As an affiliated Author from a member institution, you may be entitled to submit your manuscript without paying the article processing charge (APC) or with a discount. Check here if your institution is a member!
EJNMMI Radiopharmacy and Chemistry publishes new research in the field of development of new imaging and radionuclide based therapeutic agents for application in nuclear medicine and molecular imaging. The journal provides a platform for chemists, pharmacists and basic scientists to present their views and scientific work. In addition, the journal provides insight in novel concepts of imaging or radionuclide based therapeutic agent applications of relevance for the whole molecular imaging community. The journal reports original research articles, review papers, guidelines on application of imaging or radionuclide therapy agents, editorials, and letters to the editor. Research articles on novel radiochemistry, new radiopharmaceuticals including their first biological evaluation, molecular imaging agents including optical imaging, MRI, and hybrid probes, are the main focus of the journal. To translate imaging and radionuclide therapy agents to the clinic, legislative issues related to their production and safety can be presented as well in from of guidelines or position papers.
We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding.
Learn more here
EJNMMI Radiopharmacy and Chemistry is a new journal within the EJNMMI family to publish research in the field of new imaging and radionuclide based therapeutic agents that can be applied in nuclear medicine and molecular imaging. There is a great need for better and more specific imaging agents for better diagnosis and understanding of disease. This will finally enable improvement of patient treatment. Combination of different molecular imaging modalities to obtain the optimal diagnostic information will be boostered by the development of hybrid imaging probes. The number of applications of radionuclide therapy is increasing and more effective radiotherapeutic agents are urgently needed. Thus it can be concluded that radiopharmacy and radiochemistry are very essential for the development of nuclear medicine and molecular imaging and for its position in personalized medicine.
This new journal provides an ideal platform for chemists, pharmacists and basic scientists to promote science, but also to exchange opinions and to provide updates on developments that have effect on availability of imaging agents for the clinic such as regulatory aspects. By accepting original research articles, review papers, guidelines on application of imaging or radionuclide therapy agents, editorials, and letters to the editor I hope to establish a unique platform for our community.